Verastem begins inhibitor compound trial

Robert Forrester is the president of Verastem.

Pat Greenhouse/Globe Staff/File

Robert Forrester is the president of Verastem.

Cambridge-based Verastem Inc., which focuses on developing drugs to treat cancer by the targeted killing of cancer stem cells, said Wednesday it has initiated a phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer. The study will enroll up to 40 patients at three US locations. Verastem president and chief operating officer Robert Forrester said VS-4718 is the second compound in the company’s portfolio to enter clinical development.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of